ConCallIQ
Go Pro
Home › Alivus Life Sciences › Margin Trend

Alivus Life Sciences Margin Trend — Quarter by Quarter

Alivus Life Sciences's EBITDA margin moved from 33.0% in Q2 FY26 to 34.4% in Q4 FY26 across 3 quarters. Management commentary below explains the cost and pricing drivers mentioned on calls.

EBITDA Margin by Quarter

QuarterEBITDA Margin (%)YoY Change
Q4 FY2634.4%+230 bps
Q3 FY2636.4%+510 bps
Q2 FY2633.0%+480 bps

What management said about ebitda margin

G

Q4 FY26 · EBITDA margin guidance of 30-32% for FY27

Management expects to sustain EBITDA margins in the range of 30-32% for FY27, despite geopolitical headwinds.

G

Q3 FY26 · EBITDA margin guidance raised to 30-32%

EBITDA margin expected to be in 30-32% range going forward, up from earlier guidance of 28-30%.

G

Q2 FY26 · Sustain EBITDA margins around 30%

Management expects to sustain EBITDA margins around 30% despite absence of PLI benefits, supported by new launches and operational efficiency.